Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

OMF launches OMF Australia

Big news from Australia!

To celebrate Triple Giving Tuesday, our largest fundraising drive of the year, we want to share with you, our valued supporter, some exciting news!

We are proud to announce the launch of OMF Australia with the establishment of the Melbourne ME/CFS Collaboration, to be led by our beloved colleague and newest Collaborative Research Center (CRC) Director, Christopher Armstrong, PhD.  The Melbourne Collaboration will be the 5th addition to our global network of OMF funded CRCs that include Harvard, Stanford, Uppsala, and Montreal Universities.

We are tremendously grateful for the generous support from Emerge Australia, our Australian partner. Emerge Australia is a national organization providing information, support and advocacy for people with ME/CFS  giving hope and help to more than 250,000 Australians living with the disease.

About Christopher Armstrong

Christopher Armstrong, PhD, will be the Director of the Melbourne ME/CFS Collaboration. Chris, OMF’s former Science Liaison and Visiting Scholar at Stanford, completed his PhD in Biochemistry at the University of Melbourne and has been involved with researching ME/CFS for over a decade. An Australian native, he is perfectly positioned to lead and grow this new research hub for years to come.

The Research 

Under the direction of Dr. Armstrong, the team at the Melbourne ME/CFS Collaboration will conduct a groundbreaking research program to develop a personalized medical approach for studying and treating ME/CFS.

In its first project, the  Melbourne research team will characterize the biology of people with ME/CFS by continuously monitoring their health data and sporadically sampling and analyzing their blood and urine over the course of a year. Data will be analyzed to identify characteristics of disease severity in individuals, then compared across patients to identify patterns  helping reduce the complexity and length of the personalized medical approach.

The expected outcome is the establishment of a condensed personalized research method that can be used to track the development of ME/CFS, provide an understanding of the biology of the disease process in the individual, and monitor outcomes in clinical treatment trials.

Read more about Chris’s research

Your contribution made during the first week of OMF’s 2020 Triple Giving Tuesday will jumpstart our campaign and show your support for young, cutting edge researchers like Dr. Armstrong. It will inspire philanthropy in Australia and all of our Collaborative Research Centers across the globe, energizing our single most important fundraising effort of the year.

Donate today to ensure we can take advantage of the entire matching gift amount

Give any amount, any day of the week — and your gift will be TRIPLED!

If you’re passionate about ending ME/CFS, we encourage you to create your own online fundraiser for OMF. All donations to your fundraiser will be triple matched as well during this campaign!

In a year of great uncertainty, we find promise that the efforts to find a cure for ME/CFS continues to grow. From Australia, Sweden, Canada and the U.S., OMF is leading research — and, with your help, delivering hope for a better future.

Donate now

With hope for all,

Linda Tannenbaum
Founder & CEO/President

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager